Helen Boucher

Helen Boucher is Chief of the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, a Professor of Medicine at Tufts University School of Medicine, and Director of the Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR).

Helen Boucher
Alma materUniversity of Texas Medical School at Houston
College of the Holy Cross
OccupationPhysician
Researcher

Education

Helen Boucher graduated with an undergraduate degree in English from College of the Holy Cross, before earning her medical degree from the University of Texas Medical School at Houston.[1]

Career

Boucher has worked as a physician in the field of infectious diseases since the mid-1990s.[2] She is a professor at Tufts University[3] and the founding co-director of the Center for Integrated Management of Antimicrobial Resistance (CIMAR) along with Ralph Isberg.[4] She has also served as the Director of the Infectious Diseases Fellowship Program at the Tufts Medical Center,[5] and is currently a physician and Chief of the Division of Geographic Medicine and Infectious Diseases.[1][6] As a scholar, her research focuses on drug-resistant medical infections.[3] She has also commented on public medical issues in publications including the Washington Post.[7]

Boucher is also a member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria,[8][9] and is an associate editor of Infectious Diseases[10] and a member of the editorial board for Antimicrobial Agents and Chemotherapy.[11] Boucher is also treasurer of the Infectious Diseases Society of America.[12]

References
  1. "Holy Cross to Host Second Annual Women in Science Day | Newsroom | College of the Holy Cross". news.holycross.edu.
  2. EDT, David H. Freedman On 05/15/19 at 7:10 AM (May 15, 2019). "Doctors are running out of effective drugs because of poor financial incentives to develop them". Newsweek.
  3. Hall, William (April 9, 2018). "Superbugs: An Arms Race against Bacteria". Harvard University Press – via Google Books.
  4. "Tufts Medical Center takes on life-threatening superbug infections". March 8, 2019.
  5. Medicine, National Academies of Sciences, Engineering, and; Division, Health and Medicine; Health, Board on Global; Threats, Forum on Microbial (December 8, 2017). "Combating Antimicrobial Resistance: A One Health Approach to a Global Threat: Proceedings of a Workshop". National Academies Press – via Google Books.
  6. "'Superbug' infections are on the rise, a new CDC report says". Pittsburgh Post-Gazette.
  7. "First New Tuberculosis Drug Approved in 50 Years". The Scientist Magazine®.
  8. Turmelle, Luther (December 27, 2019). "Former New Haven drugmaker seeks bankruptcy protection". New Haven Register.
  9. Jacobs, Andrew (December 25, 2019). "Crisis Looms in Antibiotics as Drug Makers Go Bankrupt" – via NYTimes.com.
  10. "Medscape Infectious Diseases Editorial Board". www.medscape.com.
  11. Microbiology, American Society for (July 1, 2014). "Editorial Board". Antimicrobial Agents and Chemotherapy. 58 (7): A3–A3. doi:10.1128/AAC.masthead.58-7 – via aac.asm.org.
  12. "Board of Directors". www.idsociety.org.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.